In-house R&D Pipeline
Among them, SWA1211 obtained both IND approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) in March 2025, and completed first patient dosing in June 2025.
Start Your Intelligent Drug Design Journey
MolVado Small Molecule Drug Design Platform – Empowering Your R&D Breakthroughs
